TABLE 2.

Base-Case Estimates of Incremental Cost-Effectiveness Ratios

StrategyCostIncremental CostEffectivenessIncremental EffectivenessCost-EffectivenessIncremental Cost-Effectiveness
Utility as the effectiveness measure
    Conventional treatment$40 4680.8262$48 982
    iNO treatment$41 609$11410.88610.0599$46 956$19 022 per QALY
Survival as the effectiveness measure
    Conventional treatment$40 4680.8954$45 197
    iNO treatment$41 609$11410.92970.0343$44 755$33 234 per survival
  • With a ceiling ratio of $50 000 or $10 0000 per QALY or survival, the net monetary benefit for utility is $1854 or $4849, respectively, and the net monetary benefit for survival is $574 or $2289, respectively.